海尔生物(688139) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥592.19 million, representing a year-on-year increase of 53.09%[6] - Net profit attributable to shareholders for Q3 2021 was ¥125.11 million, a 6.41% increase compared to the same period last year[6] - The total revenue for the first three quarters of 2021 was ¥1.52 billion, reflecting a growth of 54.89% year-on-year[6] - Revenue increased by 54.89% driven by high growth in IoT solutions and traditional business[24] - Net profit rose by 155.20% attributed to business scale growth and investment income from disposed joint ventures[24] - The company reported a profit margin increase of 157.99% due to operational scale growth[24] - Total operating revenue for the first three quarters of 2021 reached ¥1,520,143,956.41, a significant increase from ¥981,453,217.89 in the same period of 2020, representing a growth of approximately 54.9%[47] - Net profit for the third quarter of 2021 was ¥700,445,995.03, up from ¥274,465,658.03 in the same quarter of 2020, reflecting a growth of approximately 155.0%[50] - Basic earnings per share for the third quarter of 2021 were ¥2.20, compared to ¥0.86 in the same quarter of 2020, marking an increase of about 156.0%[52] - The company reported a total comprehensive income of ¥724,903,178.40 for the third quarter of 2021, compared to ¥271,656,099.54 in the same quarter of 2020, representing an increase of approximately 167.0%[52] Research and Development - Research and development expenses amounted to ¥81.43 million in Q3 2021, a significant increase of 66.92% year-on-year, accounting for 13.75% of total revenue[9] - Research and development expenses increased by 61.97% due to investments in IoT R&D projects[24] - Research and development expenses for the first three quarters of 2021 were ¥174,004,095.97, up from ¥107,428,279.39 in 2020, reflecting an increase of approximately 62.0%[47] - The company launched new products including a program cooling instrument and a new series of centrifuges, obtaining over 20 related patents[12] Market Performance - The domestic market generated revenue of ¥1.12 billion in the first three quarters, a 66.56% increase year-on-year, driven by IoT solutions[12] - The overseas market revenue reached ¥390.97 million in the first three quarters, showing a growth of 32.79%, with Q3 growth accelerating to 79.15%[12] Cash Flow and Assets - The net cash flow from operating activities for the first three quarters was ¥442.84 million, reflecting an 8.03% increase year-on-year[6] - Cash flow from operating activities for the first three quarters of 2021 was ¥1,829,289,551.15, compared to ¥1,155,364,523.62 in 2020, indicating a growth of about 58.3%[52] - The total assets as of the end of Q3 2021 were ¥4.69 billion, a 19.08% increase compared to the end of the previous year[9] - The company's current assets totaled RMB 3,486,328,814.89, compared to RMB 2,733,965,717.27 in the previous year, indicating a growth of approximately 27.6%[37] - The company's inventory increased significantly to RMB 392,481,243.48, up from RMB 247,949,856.20, representing a growth of approximately 58.2%[37] - The total cash and cash equivalents at the end of the period stood at CNY 799,023,807.51, down from CNY 961,085,040.10 at the end of the previous year[57] Liabilities and Equity - The total liabilities amounted to RMB 2,486,328,814.89, showing an increase from the previous year's liabilities[41] - The total liabilities increased to ¥1,292,765,727.02 in 2021 from ¥1,158,084,744.73 in 2020, representing a growth of approximately 11.5%[43] - Total equity attributable to shareholders reached ¥3,391,034,403.28 in 2021, compared to ¥2,775,877,783.68 in 2020, indicating an increase of about 22.1%[43] - The company reported a significant increase in contract liabilities to RMB 393,869,028.82 from RMB 247,818,290.15, reflecting a growth of about 59%[41] Investment Activities - Cash outflow from investment activities was CNY 6,301,496,005.26, up from CNY 4,213,890,184.72 year-over-year[55] - The net cash flow from investment activities was negative at CNY -1,299,797,346.33, worsening from CNY -768,700,793.76 in the previous year[55] - The company received CNY 4,508,442,851.66 from the recovery of investments, an increase from CNY 3,400,020,000.00 in the previous year[55] - Cash paid for purchasing fixed assets and intangible assets was CNY 140,266,005.26, compared to CNY 55,598,894.72 in the same period last year[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,026[27] - The largest shareholder, Qingdao Haier Biomedical Holdings Co., Ltd., holds 31.73% of the shares[27]